rEVO Biologics, Inc.

Healthcare · Biological Products, (No Diagnostic Substances) · MA · SEC filings ↗ · Compare ⊕

Financials

SEC XBRL · annual

No structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).

Insider transactions

SEC Form 4 · most recent

6 acquisitions1 disposalsnet +2.3M shares · last 7

Insider	Date	Type	Shares	Price
Mcnamara Pamela WDirector	Jul 2, 2010	Grant	2,174	$0.46
Bullock Francis JDirector	Jul 2, 2010	Grant	4,076	$0.46
Bullock Francis JDirector	Apr 1, 2010	Grant	3,409	$0.55
Tuck Alan WDirector	Apr 1, 2010	Grant	2,727	$0.55
Mcnamara Pamela WDirector	Apr 1, 2010	Grant	1,818	$0.55
Scotland Richard AOfficer — Senior VP, Regulatory Affairs	Jan 19, 2010	Sell	14,798	$1.13
Lfb Biotechnologies S.A.S.U.Director	Jan 6, 2010	Conversion	2.3M	$2.63

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

CERTNASAUTO-GENERATED PAPER DOCUMENTSep 10, 2015
RWFORM RWSep 4, 2015
CERTNASAUTO-GENERATED PAPER DOCUMENTSep 16, 2014
8-A12BSep 16, 2014
S-1/ASep 4, 2014
S-1/AAug 14, 2014
S-1/AJul 28, 2014
S-1FORM S-1Jun 25, 2014
DRS/AJun 10, 2014
DRS/AMay 21, 2014
DRSApr 11, 2014
15-12GDec 15, 2010
EFFECTDec 13, 2010
EFFECTDec 13, 2010
EFFECTDec 13, 2010

Event-driven situations (1)

Dec 9, 2010Going privatecompleted

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.